Evodiamine Attenuates P2X

Area of Science:

• Endocrinology
• Molecular Biology
• Cell Biology

Background:

• Insulin resistance and type 2 diabetes mellitus (T2DM) are global health issues.
• Elevated free fatty acids (FFAs) are strongly linked to insulin resistance and T2DM.
• The P2X7 receptor, an ATP-gated ion channel, plays roles in inflammation and cellular responses.

Purpose of the Study:

• To investigate the role of the P2X7 receptor in high FFA-induced pathological changes in HUVECs.
• To evaluate the potential protective effects of evodiamine against these changes.

Main Methods:

• Treatment of HUVECs with high FFAs.
• Assessment of P2X7 receptor expression (mRNA and protein).
• Measurement of cytotoxicity, ATP release, reactive oxygen species (ROS) production, nitric oxide (NO) formation, and immune cell adhesion.
• Analysis of TNF-α expression and ERK 1/2 phosphorylation.

Main Results:

• High FFAs upregulated P2X7 receptor expression, increased cytotoxicity, ATP release, ROS production, and immune cell adhesion, while decreasing NO formation.
• Evodiamine suppressed high FFA-induced P2X7 receptor expression.
• Evodiamine ameliorated cytotoxicity, ATP release, ROS production, and immune cell adhesion.
• Evodiamine restored NO formation and inhibited P2X7-dependent TNF-α expression and ERK 1/2 phosphorylation.

Conclusions:

• Evodiamine effectively counteracts high FFA-induced P2X7 receptor upregulation in HUVECs.
• Evodiamine mitigates oxidative stress and inflammatory responses mediated by P2X7 receptor signaling.
• These findings highlight evodiamine's potential as a therapeutic agent for conditions associated with high FFAs, insulin resistance, and T2DM.